Investigators designed and externally validated a prostate cancer death prediction model for risk stratification of men at the point of PSA screening.

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...

Experts called for urgent action to tackle air pollution after evidence suggested traffic and industrial fumes may contribute ...

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

Treatment with Leuprorelin did not improve OS or disease-specific survival for patients with nonmetastatic, high-risk prostate cancer who have undetectable PSA levels, while causing more adverse ...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...

HIGHLIGHTSFollowing an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed ...

Join Tom and Mike from Take Time to Travel as they share a personal health update that has changed their winter travel plans.

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Financial Guidance As of September 30, 2025, cash, cash equivalents and investments totaled $413.0 million, which the company expects will be sufficient to fund its operating plan into 2H 2028, beyond ...

After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once, 20 to 30 percent will show signs of recurrence after the five-year mark ...